Brought to you by 
Merck KGAA to pay over $7bn for Millipore
08 Mar 2010
Executive Summary
In an effort to boost its laboratory business and strengthen its US presence, Merck KGAA has agreed to pay $107 per share to acquire all of publicly traded life sciences firm Millipore. Including net debt of $1.2bn, the deal is valued at about $7.2bn. The per-share price represents a 54% premium to Millipore's stock value in the ten days preceding the company's announcement that it was exploring strategic business alternatives, such as a potential sale.
Deal Industry
- Medical Devices
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck KGAA to pay over $7bn for Millipore
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice